Complement C3: an emerging risk factor in cardiometabolic disease

[1]  A. Carter,et al.  A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3 , 2012, Diabetologia.

[2]  K. Cianflone,et al.  Complement C3 and cleavage products in cardiometabolic risk. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[3]  E. Feskens,et al.  The cross‐sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study) , 2011, European journal of clinical investigation.

[4]  J. Wojta,et al.  Complement in atherosclerosis: friend or foe? , 2011, Journal of thrombosis and haemostasis : JTH.

[5]  J. Moreno-Navarrete,et al.  Complement Factor H Is Expressed in Adipose Tissue in Association With Insulin Resistance , 2009, Diabetes.

[6]  O. Wagner,et al.  Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction , 2009, Thrombosis and Haemostasis.

[7]  J. Lamb,et al.  The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration and Activation , 2009, Diabetes.

[8]  L. Wen,et al.  Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. , 2009, Journal of autoimmunity.

[9]  Jing Wu,et al.  Palmitate and oleate induction of acylation stimulating protein resistance in 3T3‐L1 adipocytes and preadipocytes , 2008, Journal of cellular biochemistry.

[10]  M. Zoli,et al.  Serum C3 Is a Stronger Inflammatory Marker of Insulin Resistance Than C-Reactive Protein, Leukocyte Count, and Erythrocyte Sedimentation Rate , 2007, Diabetes Care.

[11]  John D Lambris,et al.  The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.

[12]  K. Cianflone,et al.  Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. , 2007, The Journal of endocrinology.

[13]  S. Thiel,et al.  Complement activation and diabetic vascular complications. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[14]  S. Pay,et al.  Hyperhomocysteinemia in patients with Behçet’s disease: is it due to inflammation or therapy? , 2005, Rheumatology International.

[15]  K. Eriksson,et al.  Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. , 2005, Diabetes.

[16]  W. Couser,et al.  Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? , 2003, Journal of the American Society of Nephrology : JASN.

[17]  K. Cianflone,et al.  Critical review of acylation-stimulating protein physiology in humans and rodents. , 2003, Biochimica et biophysica acta.

[18]  C. Gerhardinger,et al.  Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. , 2002, Diabetes.

[19]  Sucharit Bhakdi,et al.  Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. , 2002, Investigative ophthalmology & visual science.

[20]  G. Rosoklija,et al.  Local activation of the complement system in endoneurial microvessels of diabetic neuropathy , 2000, Acta Neuropathologica.

[21]  N. Hotta,et al.  Complement activation products in the urine from proteinuric patients. , 1998, Journal of the American Society of Nephrology : JASN.

[22]  Shats-Tseytlina Ea,et al.  Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? , 1994 .

[23]  G. Hansson,et al.  Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[24]  L. Morin,et al.  Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. , 1987, Clinical chemistry.

[25]  John D Lambris,et al.  Interactions between coagulation and complement—their role in inflammation , 2011, Seminars in Immunopathology.

[26]  K. Eriksson,et al.  Complement C 3 Is a Risk Factor for the Development of Diabetes A Population-Based Cohort Study , 2005 .

[27]  D. Dhall,et al.  Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.